Your browser doesn't support javascript.
loading
Heterozygous PNPT1 Variants Cause Spinocerebellar Ataxia Type 25.
Barbier, Mathieu; Bahlo, Melanie; Pennisi, Alessandra; Jacoupy, Maxime; Tankard, Rick M; Ewenczyk, Claire; Davies, Kayli C; Lino-Coulon, Patricia; Colace, Claire; Rafehi, Haloom; Auger, Nicolas; Ansell, Brendan R E; van der Stelt, Ivo; Howell, Katherine B; Coutelier, Marie; Amor, David J; Mundwiller, Emeline; Guillot-Noël, Lena; Storey, Elsdon; Gardner, R J McKinlay; Wallis, Mathew J; Brusco, Alfredo; Corti, Olga; Rötig, Agnès; Leventer, Richard J; Brice, Alexis; Delatycki, Martin B; Stevanin, Giovanni; Lockhart, Paul J; Durr, Alexandra.
  • Barbier M; Sorbonne Université, Institut du Cerveau-Paris Brain Institute-ICM, Inserm, CNRS, APHP, Hôpital de la Pitié Salpêtrière, Paris, France.
  • Bahlo M; Population Health and Immunity Division, The Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.
  • Pennisi A; Department of Medical Biology, University of Melbourne, Melbourne, Victoria, Australia.
  • Jacoupy M; Necker Hospital, APHP, Reference Center for Mitochondrial Diseases, Genetics Department, Institut Imagine, University of Paris, Paris, France.
  • Tankard RM; Inserm UMR_S1163, Institut Imagine, Paris, France.
  • Ewenczyk C; Sorbonne Université, Institut du Cerveau-Paris Brain Institute-ICM, Inserm, CNRS, APHP, Hôpital de la Pitié Salpêtrière, Paris, France.
  • Davies KC; Population Health and Immunity Division, The Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.
  • Lino-Coulon P; Department of Medical Biology, University of Melbourne, Melbourne, Victoria, Australia.
  • Colace C; Sorbonne Université, Institut du Cerveau-Paris Brain Institute-ICM, Inserm, CNRS, APHP, Hôpital de la Pitié Salpêtrière, Paris, France.
  • Rafehi H; Bruce Lefroy Centre, Murdoch Children's Research Institute, Melbourne, Victoria, Australia.
  • Auger N; Department of Paediatrics, University of Melbourne, Melbourne, Victoria, Australia.
  • Ansell BRE; Sorbonne Université, Institut du Cerveau-Paris Brain Institute-ICM, Inserm, CNRS, APHP, Hôpital de la Pitié Salpêtrière, Paris, France.
  • van der Stelt I; Sorbonne Université, Institut du Cerveau-Paris Brain Institute-ICM, Inserm, CNRS, APHP, Hôpital de la Pitié Salpêtrière, Paris, France.
  • Howell KB; Population Health and Immunity Division, The Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.
  • Coutelier M; Department of Medical Biology, University of Melbourne, Melbourne, Victoria, Australia.
  • Amor DJ; Sorbonne Université, Institut du Cerveau-Paris Brain Institute-ICM, Inserm, CNRS, APHP, Hôpital de la Pitié Salpêtrière, Paris, France.
  • Mundwiller E; Paris Sciences Lettres Research University, EPHE, Paris, France.
  • Guillot-Noël L; Population Health and Immunity Division, The Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.
  • Storey E; Department of Medical Biology, University of Melbourne, Melbourne, Victoria, Australia.
  • Gardner RJM; Population Health and Immunity Division, The Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.
  • Wallis MJ; Department of Medical Biology, University of Melbourne, Melbourne, Victoria, Australia.
  • Brusco A; Donders Centre for Neuroscience, Faculty of Science, Radboud University, Nijmegen, The Netherlands.
  • Corti O; Department of Paediatrics, University of Melbourne, Melbourne, Victoria, Australia.
  • Rötig A; Department of Neurology, Royal Children's Hospital, Melbourne, Victoria, Australia.
  • Leventer RJ; Murdoch Children's Research Institute, Melbourne, Victoria, Australia.
  • Brice A; Sorbonne Université, Institut du Cerveau-Paris Brain Institute-ICM, Inserm, CNRS, APHP, Hôpital de la Pitié Salpêtrière, Paris, France.
  • Delatycki MB; Paris Sciences Lettres Research University, EPHE, Paris, France.
  • Stevanin G; Department of Paediatrics, University of Melbourne, Melbourne, Victoria, Australia.
  • Lockhart PJ; Murdoch Children's Research Institute, Melbourne, Victoria, Australia.
  • Durr A; Sorbonne Université, Institut du Cerveau-Paris Brain Institute-ICM, Inserm, CNRS, APHP, Hôpital de la Pitié Salpêtrière, Paris, France.
Ann Neurol ; 92(1): 122-137, 2022 07.
Article en En | MEDLINE | ID: mdl-35411967
ABSTRACT

OBJECTIVE:

Dominant spinocerebellar ataxias (SCA) are characterized by genetic heterogeneity. Some mapped and named loci remain without a causal gene identified. Here we applied next generation sequencing (NGS) to uncover the genetic etiology of the SCA25 locus.

METHODS:

Whole-exome and whole-genome sequencing were performed in families linked to SCA25, including the French family in which the SCA25 locus was originally mapped. Whole exome sequence data were interrogated in a cohort of 796 ataxia patients of unknown etiology.

RESULTS:

The SCA25 phenotype spans a slowly evolving sensory and cerebellar ataxia, in most cases attributed to ganglionopathy. A pathogenic variant causing exon skipping was identified in the gene encoding Polyribonucleotide Nucleotidyltransferase PNPase 1 (PNPT1) located in the SCA25 linkage interval. A second splice variant in PNPT1 was detected in a large Australian family with a dominant ataxia also mapping to SCA25. An additional nonsense variant was detected in an unrelated individual with ataxia. Both nonsense and splice heterozygous variants result in premature stop codons, all located in the S1-domain of PNPase. In addition, an elevated type I interferon response was observed in blood from all affected heterozygous carriers tested. PNPase notably prevents the abnormal accumulation of double-stranded mtRNAs in the mitochondria and leakage into the cytoplasm, associated with triggering a type I interferon response.

INTERPRETATION:

This study identifies PNPT1 as a new SCA gene, responsible for SCA25, and highlights biological links between alterations of mtRNA trafficking, interferonopathies and ataxia. ANN NEUROL 2022;92122-137.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Interferón Tipo I / Ataxia Cerebelosa / Ataxias Espinocerebelosas Límite: Humans País como asunto: Europa / Oceania Idioma: En Año: 2022 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Interferón Tipo I / Ataxia Cerebelosa / Ataxias Espinocerebelosas Límite: Humans País como asunto: Europa / Oceania Idioma: En Año: 2022 Tipo del documento: Article